Clinical Trials Sponsored by Peter Zage

Total 507 results

Peter Zage
Exelixis

Recruiting

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Solid Tumor

United States
CAGE Bio Inc.
John Peter Smith Hospital

Recruiting

An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection

Fungal Infection | Onychomycosis | Tinea Unguium

United States
Peter G Mavrelis

Completed

GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery (GERD)

Gastro Esophageal Reflux

United States
Peter Brehm GmbH

Terminated

Prospective Post Market Clinical Follow-Up of the Primary Knee Endoprosthesis BPK-S Integration

Osteoarthritis, Knee | Joint Instability

Austria
Sage Therapeutics

Completed

An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus

Tinnitus

United States
Sage Therapeutics

Completed

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

Parkinson Disease | Cognitive Dysfunction

United States
Sage Therapeutics

Completed

Evaluate SAGE-547 in Participants With Essential Tremor

Essential Tremor

United States
Sage Therapeutics

Completed

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus (SRSE)

Super-refractory Status Epilepticus

United States
Sage Therapeutics

Completed

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Healthy Volunteer

United States
Sage Therapeutics

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Huntington Disease

United States
Sage Therapeutics

Completed

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

Postpartum Depression

United States
Sage Therapeutics

Completed

A Study With SAGE-547 for Super-Refractory Status Epilepticus

Super-Refractory Status Epilepticus

United States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Serbia, Spain, Sweden, United Kingdom
Sage Therapeutics

Completed

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

Postpartum Depression

United States
Sage Therapeutics

Completed

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

Healthy Volunteer

United States
Sage Therapeutics

Withdrawn

A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)

Postpartum Depression
Anguria, Peter, M.D.

Completed

Determinants of Pterygium Occurrence and Recurrence in a Rural African Population

Pterygium

South Africa
Sage Therapeutics

Recruiting

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Huntington Disease

United States, Canada
Sage Therapeutics

Recruiting

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Huntington's Disease

United States, Australia, Canada, United Kingdom
Sage Therapeutics

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor

Essential Tremor

United States
Sage Therapeutics

Active, not recruiting

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Huntington Disease

United States
Sage Therapeutics

Completed

A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting

Postpartum Depression

United States
Sage Therapeutics

Terminated

A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

COVID-19 | Acute Respiratory Distress Syndrome

United States
Sage Therapeutics

Completed

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

Severe Postpartum Depression

United States
Sage Therapeutics

Recruiting

A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

Essential Tremor

United States
Sage Therapeutics

Active, not recruiting

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease | Mild Dementia

United States, Puerto Rico
Sage Therapeutics

Completed

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Parkinson Disease | Cognitive Dysfunction

United States
Sage Therapeutics

Completed

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Cognitive Dysfunction | Alzheimer Disease | Mild Dementia

United States
Sage Therapeutics

Completed

A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)

Post Partum Depression

United States
Sage Therapeutics

Completed

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

Healthy Volunteer

United States
Sage Therapeutics

Completed

A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Healthy Volunteer

United States
Sage Therapeutics

Completed

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

Postpartum Depression

United States
Sage Therapeutics

Approved for marketing

Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression

Postpartum Depression
Sage Therapeutics

No longer available

An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus

Super-Refractory Status Epilepticus
Peter Hovind

Not yet recruiting

Assessing Repeatability and Intra-individual Variability in [O15]H2O-PET Myocardial Perfusion Imaging (Heart-Wave)

Myocardial Blood Flow

Denmark
Peter Gillgren

Completed

Trial of Surgical Excision Margins in Thick Primary Melanoma - 2

Melanoma | Surgery | Treatment Outcome
Peter Kristensen

Recruiting

DIAbetes TEam and Cgm in Managing Hospitalised Patients With Diabetes (DIATEC)

Diabetes Mellitus, Type 2

Denmark
Peter atef

Recruiting

Portal Vein Flow Velocity as a Screening Tool for Oesophageal Varices in Cirrhotic Patients (Portalflow)

Cirrhosis Portal

Egypt
Peter Nymberg

Withdrawn

Equine Assisted Services in Children and Adolescents With Mental Illness (EASiCAM)

Depression | Anorexia Nervosa | Anxiety Disorders | Anxiety | Mental Disorder in Adolescence | Mental Disorders, Child | School Fear

Sweden
Peter Lommer

Completed

The Impact of ROTO Track® in Helping Patients With Diabetes Rotate Their Insulin Injections Better (ROTOone)

Diabetes

Denmark
Peter Studinger

Suspended

Bioimpedance Analysis in Chronic Heart Failure

Heart Failure

Hungary
Peter Moosmann
Kantonsspital Aarau

Completed

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Lymphoma, Non-Hodgkin
Sage Therapeutics
Biogen

Recruiting

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Russell Sage College

Completed

Effectiveness of Music Practical Examinations

Stress | Test Anxiety

United States
GlaxoSmithKline
Sage Analytica

Completed

Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom From 1995 to 2009

Respiratory Syncyctial Virus Vaccines
GlaxoSmithKline
Sage Analytica

Completed

Influenza Burden Assessment in the United Kingdom, 1996-2008

Influenza
Sage Therapeutics
Biogen

Active, not recruiting

Study to Evaluate SAGE-324 in Participants With Essential Tremor

Essential Tremor

United States
Sage Therapeutics
Biogen

Completed

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
CAGE Bio Inc.

Not yet recruiting

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

Atopic Dermatitis
The Sage Colleges

Completed

Ultrasound Treatment in the Management of Plantar Fasciitis

Plantar Fascitis
The Sage Colleges

Unknown

The Effectiveness of Ultrasound Treatment in the Management of Plantar Fasciitis

Plantar Fascitis

United States

3

Subscribe